Characterization and Clinical Relevance of Endometrial CAFs: Correlation between Post-Surgery Event and Resistance to Drugs
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms24076449 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Raed Sulaiman und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Avera Research Institute, Sioux Falls, SD 57105, USA. Hauptthemen laut MEDLINE: Cancer-Associated Fibroblasts, Endometrial Neoplasms. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Avera Cancer Institute.
Abstract (Originalsprache)
Cancer-associated fibroblasts (CAFs) within a solid tumor can support the progression of cancer. We studied the identification and characterization of patient-derived endometrial CAFs in the context of their clinical relevance in endometrial cancers. We established patient-derived primary cultures of CAFs from surgically resected tumors (TCAF) and tumor-adjacent normal (NCAF) tissues in 53 consented patients with success rates of 97.7% and 75%, respectively. A passage of CAF was qualified by the (1) absence of CK 8,18,19, EpCAM, CD45, and CD31, and (2) presence of SMAalpha, S100A4, CD90, FAP, TE-7, CD155, PD-L1, TGFB, PDGFRA (qRT-PCR, flow cytometry, Western blot, ICC). Out of the 44 established CAFs, 31 were aggressive (having an early, i.e., 4–7 week, establishment time and/or >3 passages) compared to 13 which were non-aggressive. A post-surgery-event (PSE) was observed in 7 out of 31 patients bearing aggressive CAFs, 2 of whom were also positive for CTCs, while none of the 13 patients bearing non-aggressive CAFs had events. A positive correlation was found between patients with grade 3 (p = 0.025) as well as stage 3/4 diseases (p = 0.0106) bearing aggressive CAFs and the PSE. Finally, aggressive TCAFs from patients with PSE resisted the effects of paclitaxel and lenvatinib on the growth of HUVEC and endometrial tumor cells. Our study is the first to report a correlation between the PSE and the aggressive nature of CAFs in endometrial cancers and provides an undeniable reason to study the in-depth mechanism of CAF function towards the development of treatment resistance in endometrial cancers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, Avera Research Institute, Sioux Falls, SD 57105, USA.
- Translational Oncology Laboratory, Avera Research Institute, Sioux Falls, SD 57105, USA.
- Department of Internal Medicine, University of South Dakota SSOM, USD, Sioux Falls, SD 57105, USA.
- Viecure, Greenwood Village, CO 80111, USA.
- Assistant VP Outpatient Cancer Clinics, Avera Cancer Institute, Sioux Falls, SD 57105, USA.
- Department of Gynecologic Oncology, Avera Cancer Institute, Sioux Falls, SD 57105, USA.
ORCID-Profile: Jennifer C Aske, Nandini Dey
Förderung
- Avera Cancer Institute
Zitieren
APA
Sulaiman, R., De, P., Aske, J. C., Lin, X., Dale, A., Gaster, K., Espaillat, L. R., Starks, D., & Dey, N. (2023). Characterization and Clinical Relevance of Endometrial CAFs: Correlation between Post-Surgery Event and Resistance to Drugs. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24076449
Vancouver
Sulaiman R, De P, Aske JC, Lin X, Dale A, Gaster K, et al. Characterization and Clinical Relevance of Endometrial CAFs: Correlation between Post-Surgery Event and Resistance to Drugs. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24076449
BibTeX
@article{Sulaiman2023,
author = {Sulaiman, Raed and De, Pradip and Aske, Jennifer C and Lin, Xiaoqian and Dale, Adam and Gaster, Kris and Espaillat, Luis Rojas and Starks, David and Dey, Nandini},
title = {Characterization and Clinical Relevance of Endometrial CAFs: Correlation between Post-Surgery Event and Resistance to Drugs},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms24076449}
}
EUVIMED